Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. granted options to purchase 125,600 shares of its common stock to three new employees on June 30, 2026. These inducement grants, made under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $1.14 per share, matching the closing price on the grant date. The options vest over four years, with a 10-year term, contingent on continued employment.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA) granted stock options to three new employees on June 30, 2026, for an aggregate of 125,600 shares. These options were an inducement for employment, granted under Nasdaq Listing Rule 5635(c)(4), with an exercise price of $1.14 per share, vesting over four years. Akebia Therapeutics is a biopharmaceutical company focused on kidney disease.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. announced incentive grants to three new employees to purchase an aggregate of 125,600 shares of common stock. These options were granted on June 30, 2026, as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is $1.14 per share, and the options vest over four years, subject to continued service.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA) granted stock options for an aggregate of 125,600 shares to three newly-hired employees on June 30, 2026. These grants, made under Nasdaq Listing Rule 5635(c)(4), serve as an inducement for employment. The options have an exercise price of $1.14 per share, matching the closing price on the grant date, and vest over four years.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics granted stock options to three new employees to purchase an aggregate of 125,600 shares of common stock. These inducement grants, made on June 30, 2026, are in accordance with Nasdaq Listing Rule 5635(c)(4) and aim to incentivize the new hires. The options have an exercise price of $1.14 per share, matching the closing price on the grant date, and vest over four years based on continued employment.
Akebia Therapeutics (AKBA) CFO sells 56K shares in tax sell-to-cover
Akebia Therapeutics' SVP, CFO, CBO & Treasurer, Erik Ostrowski, sold 56,019 shares of common stock at $1.11 per share on June 29, 2026. This "sell to cover" transaction was automatic, intended to satisfy tax withholding obligations related to restricted stock units granted on June 28, 2024. After the sale, Ostrowski directly holds 616,616 shares of Akebia common stock.
Akebia Therapeutics - Voice Trial Meets Stopp
This article reports that Akebia Therapeutics' Voice Trial has been stopped. The specific details or reasons for the trial stoppage are not provided in this very brief content.
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036
Akebia Therapeutics (AKBA) has enhanced the patent protection for its flagship therapy, Vafseo (vadadustat), securing a new patent listing in the FDA's Orange Book and eligibility for a five-year extension on a composition of matter patent, extending protection through 2036. This strengthens the company's existing patent portfolio and supports the long-term commercial value of Vafseo. Additionally, Akebia reported strong first-quarter 2026 financial results, with Vafseo net product revenue reaching $15.8 million and a significant increase in patients and prescribers, while also advancing its kidney disease pipeline.
Akebia: VOICE trial stopped early after vadadustat shows superiority on primary composite endpoint
Akebia's VOICE trial for Vafseo was stopped early due to the drug demonstrating superiority on the primary composite endpoint of all-cause mortality and hospitalization. An interim analysis revealed Vafseo's non-inferiority and superiority with a win odds of 1.16. While hospitalizations decreased, there was no significant difference in mortality rates compared to ESA.
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
U.S. Renal Care and Akebia Therapeutics announced an interim analysis of the VOICE trial for Vafseo (vadadustat) in patients with anemia due to chronic kidney disease on dialysis. The trial was stopped early due to overwhelming statistical evidence of improved safety outcomes, specifically a significant reduction in hospitalizations for patients treated with Vafseo compared to erythropoiesis-stimulating agents (ESAs). The companies plan to present the full data at an upcoming scientific meeting, highlighting Vafseo's potential clinical benefits.
Akebia Therapeutics (AKBA) lists 56,019 shares after RSU vesting on 06/28/2026
Akebia Therapeutics submitted a Form 144 notice regarding the vesting of restricted stock units (RSUs) on June 28, 2026. The filing indicates 56,019 shares of common stock are involved in connection with this equity compensation event. The notice also references Nasdaq and a filing/exchange line date of June 29, 2026.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akebia Therapeutics, Inc. (AKBA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Akebia Therapeutics, Inc. (AKBA) purchasers following a significant stock price drop. This decline occurred after Akebia announced on October 28, 2025, that it failed to reach alignment with the FDA on the VALOR clinical trial design for vadadustat, leading the company to abandon plans for a broad label for Vafseo for CKD non-dialysis dependent patients. The firm encourages investors affected by this news to connect with them for the investigation.
Price to sales forward of Akebia Therapeutics, Inc. – NASDAQ:AKBA
This article provides limited financial information for Akebia Therapeutics, Inc. (NASDAQ: AKBA), specifically mentioning its "Price to sales forward" metric. The content primarily lists navigation and product categories for TradingView, the platform hosting the information, rather than delving into detailed financial analysis of AKBA.
Price to book forward of Akebia Therapeutics, Inc. – NASDAQ:AKBA
The article displays the "Price to book forward" for Akebia Therapeutics, Inc. (NASDAQ: AKBA) on the TradingView platform. It shows the company's stock market information, financial data, and other related services offered by TradingView, although specific numerical values for the "Price to book forward" are not present. The content primarily highlights the structure and various functionalities of the TradingView interface for this particular stock.
Akebia Therapeutics, Inc. Actuals & Estimates (NASDAQ:AKBA)
This article provides an overview of Akebia Therapeutics, Inc. (AKBA) stock, including current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions such as market capitalization, earnings reports, revenue, net income, and employee count. The piece also includes a disclaimer that the information is not investment advice.
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch
This article highlights Akebia Therapeutics (AKBA), Atea Pharmaceuticals (AVIR), and Stitch Fix (SFIX) as promising penny stocks. It details their financial health, operations, market capitalization, recent developments, and challenges, emphasizing their growth potential despite current unprofitability or debt levels. The piece also notes that these companies demonstrate positive cash flow or strong clinical pipelines, making them noteworthy in the volatile penny stock market.
AKBA Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Akebia Therapeutics, Inc. (AKBA) stock, based on analyst ratings. It includes current stock performance metrics, market capitalization, earnings details, and upcoming reports, along with other financial data and historical price information.
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch
This article highlights three promising penny stocks—Akebia Therapeutics (AKBA), Atea Pharmaceuticals (AVIR), and Stitch Fix (SFIX)—for investors to consider amidst a fluctuating U.S. market. Each company is analyzed for its financial health, growth potential, and recent developments, despite current unprofitability for Akebia and Atea, and ongoing challenges for Stitch Fix. The piece emphasizes the importance of strong fundamentals and growth potential for navigating market conditions.
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch
This article highlights three promising penny stocks: Akebia Therapeutics (AKBA), Atea Pharmaceuticals (AVIR), and Stitch Fix (SFIX). Akebia Therapeutics is a biopharmaceutical company focusing on kidney disease, showing reduced losses and strong cash flow despite being unprofitable. Atea Pharmaceuticals, also in biopharmaceuticals, is advancing its antiviral drug pipeline with no debt. Stitch Fix, an online clothing and accessories retailer, has reduced losses and maintains a stable revenue outlook despite legal challenges.
Akebia Therapeutics (NASDAQ: AKBA) investors back share increase and executive pay
Akebia Therapeutics stockholders approved an increase in authorized capital stock from 375 million to 525 million shares, and common stock from 350 million to 500 million shares, at their 2026 annual meeting. They also re-elected three Class III directors, approved executive officer compensation on an advisory basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders recommended that future advisory votes on executive compensation occur annually.
Akebia Therapeutics (AKBA) director receives RSU and stock option grants
Akebia Therapeutics director Leanne M. Zumwalt has been granted 35,700 shares of common stock as restricted stock units (RSUs) and a stock option for 53,600 shares with an exercise price of $1.02 per share. Both the RSUs and stock option will vest 100% on the first anniversary of the grant date, or potentially earlier, provided she continues her service to the company. Following these grants, Zumwalt's direct common stock holdings in Akebia Therapeutics now total 145,100 shares.
Akebia Therapeutics (AKBA) grants RSUs and stock options to director Rogers
Akebia Therapeutics, Inc. (AKBA) director Michael W. Rogers has been granted 35,700 restricted stock units (RSUs) and a stock option for 53,600 shares with an exercise price of $1.02 per share. Both awards, granted on June 17, 2026, will vest in full on the first anniversary of the grant date, or earlier immediately before the first annual stockholder meeting, contingent on his continuous service. Following these transactions, Rogers directly holds 197,429 shares of common stock and 53,600 stock options.
[Form 4] Akebia Therapeutics, Inc. Insider Trading Activity
Akebia Therapeutics director Ron Frieson was granted 35,700 restricted stock units and stock options for 53,600 shares at an exercise price of $1.02, as part of his director compensation. Both the RSUs and stock options will vest 100% on the first anniversary of the June 17, 2026 grant date or earlier. Following these awards, his direct common stock holdings increased to 165,200 shares.
Akebia Therapeutics (AKBA) awards RSUs and stock options to director Adams
Akebia Therapeutics (AKBA) director Adrian Adams was granted 35,700 restricted stock units and a stock option for 53,600 shares, with an exercise price of $1.02 per share. These equity awards, granted under the company's 2023 Stock Incentive Plan, are set to vest one year from the grant date or immediately before the first annual stockholder meeting, contingent on his continued service. Following these grants, Adams' direct holdings in common stock total 236,200 shares.
Akebia Therapeutics Inc (AKBA) Institutional Confidence
The article discusses the institutional confidence in Akebia Therapeutics Inc (AKBA), noting its current institutional shareholding score of 3.00, placing it 94th in the Pharmaceuticals industry. Institutional shareholding has increased to 46.96%, a quarter-over-quarter rise of 1.21%. Key institutional shareholders include BlackRock, State Street, and Geode Capital Management.
AKBA: All proposals passed, including director elections and share authorization increase
Akebia Therapeutics, Inc. (AKBA) held its AGM 2026 where all five presented proposals passed. These proposals included the election of directors, an increase in share authorization, and the ratification of auditors. The results will be officially filed in Form 8-K.
Akebia Therapeutics (AKBA) AGM 2026 Summary
Akebia Therapeutics (AKBA) held its 2026 Annual General Meeting (AGM) virtually, with approximately 71% of shares represented. Key outcomes included the election of three Class III directors, approval to increase authorized capital and common stock, and ratification of Ernst & Young LLP as the independent auditor. Shareholder advisory votes on executive compensation and its annual frequency also passed.
Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Akebia Therapeutics Inc (AKBA). It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also offers general market data for AKBA, including its market cap and recent stock performance.
Akebia Therapeutics sees Vafseo uptake rising as access and pipeline milestones near
The provided article content is just "MSN", which is insufficient to generate a summary or extract any meaningful information about Akebia Therapeutics or its drug Vafseo. It appears the content of the article is missing.
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Akebia Therapeutics announced the strengthening of its Vafseo (vadadustat) patent portfolio with a new patent granted and eligibility for a 5-year extension on a composition of matter patent. This expands Vafseo's intellectual property protective measures, with 14 patents now listed in the Orange Book and expiration dates extending to 2036. The company emphasizes its commitment to making Vafseo a standard of care for dialysis patients, reinforcing its competitive position in the dialysis market.
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Akebia Therapeutics announced the strengthening of its Vafseo (vadadustat) patent portfolio with a newly granted patent and eligibility for a 5-year extension on a composition of matter patent. This expands their intellectual property with 14 Orange Book-listed patents, extending protection until 2036. The company believes this reinforces its competitive position and commitment to making Vafseo, approved for anemia in CKD patients on dialysis, a standard of care.
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Akebia Therapeutics announced that a new patent has been granted and listed in the Orange Book, and a composition of matter patent for Vafseo (vadadustat) is eligible for a 5-year extension. These developments strengthen the company's intellectual property for Vafseo, which now includes 14 Orange Book listed patents with expiration dates extending to 2036. Vafseo, approved in March 2024 for anemia in dialysis patients, has no other oral HIF-PH inhibitors in the U.S. market or development.
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction
Akebia Therapeutics (AKBA) shares rose 7% due to optimism surrounding its clinical pipeline and projected significant revenue growth for its anemia drug, Vafseo, in 2026. The company plans to start a mid-stage trial for AKB-097 in rare kidney diseases in late 2026 and expects strong Vafseo sales from expanded access and improved adherence rates. Despite a Q4 net loss per share that missed analyst estimates, the company's cash reserves are expected to fund operations for at least two years.
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Akebia Therapeutics (NASDAQ:AKBA) is experiencing increased uptake of its Vafseo treatment for anemia in chronic kidney disease patients, with a 28% rise in prescribing physicians and a 60% increase in patients on therapy. The company anticipates further expansion after the TDAPA period, leading to potentially universal patient access, and highlighted upcoming pipeline milestones including VOCAL data in Q4 and VOICE results in Q1 2027. Akebia also reported two years of cash runway and advancing pipeline programs for rare renal diseases and acute kidney injury.
AKBA: Vafseo growth accelerates, pipeline advances, and broad access expected post-2026
Akebia Therapeutics (AKBA) is experiencing significant growth with its Vafseo product, driven by increasing prescribers and patients, and anticipating accelerated adoption by DaVita in the latter half of the year. The company's pipeline includes praliciguat for FSGS, AKB-097 for rare renal diseases, and AKB-9090 for AKI, with key data readouts and broader market access expected through 2027. This information is based on a transcript from the Jefferies Global Healthcare Conference 2026.
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Akebia Therapeutics (AKBA) is observing increased Vafseo uptake, marked by a 28% rise in prescribing physicians and a 60% quarter-over-quarter increase in patients, as the company approaches key access and pipeline milestones. The company anticipates expanded patient access post-TDAPA period despite expected pricing declines, and it continues to advance its renal disease pipeline with several studies including VOCAL, VOICE, and programs for FSGS, C3G, lupus nephritis, IgA nephropathy, and acute kidney injury. Akebia also highlighted its financial stability with over two years of cash runway.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. announced that it granted options to a new employee to purchase 8,400 shares of common stock on May 29, 2026, as an inducement for employment. These options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $1.02, vesting over four years with a 10-year term. The company, headquartered in Cambridge, Massachusetts, focuses on improving the lives of individuals with kidney disease.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. announced it granted options to purchase 8,400 shares of its common stock to a newly hired employee on May 29, 2026. These inducement grants, made under Nasdaq Listing Rule 5635(c)(4), carry an exercise price of $1.02 per share, mirroring the closing price on the grant date. The options will vest over four years, subject to continued employment, aiding the biopharmaceutical company in its mission to improve the lives of individuals with kidney disease.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. reported inducement grants under Nasdaq Listing Rule 5635(c)(4), granting options to purchase 8,400 shares of its common stock to a newly-hired employee on May 29, 2026. The options have an exercise price of $1.02 per share and vest over four years, contingent on continued employment. These grants are part of the company's inducement award program to attract new talent.
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced that Erik Ostrowski, CFO, and Nicholas Grund, CCO, will present at the 2026 Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2026, at 7:35 AM ET in New York, NY, and a live webcast will be available on Akebia's investor website. A replay will also be accessible for 90 days following the event.
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Akebia Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 7:35 AM ET. Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will represent the company. A live webcast and replay of the presentation will be available through Akebia’s investor relations website.
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Akebia Therapeutics announced that Erik Ostrowski, CFO and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The presentation will be webcast live and a replay will be available for 90 days. The company, focused on kidney disease, will participate in the conference held in New York.
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced that its Chief Financial and Business Officer, Erik Ostrowski, and Chief Commercial Officer, Nicholas Grund, will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, in New York. A live webcast and replay of the presentation will be available on the company's investor relations website. The company focuses on bettering the lives of people impacted by kidney disease.
Kidney disease-focused Akebia to present at NY healthcare conference
Akebia Therapeutics (NASDAQ: AKBA) announced that its Chief Financial and Business Officer, Erik Ostrowski, and Chief Commercial Officer, Nicholas Grund, will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The presentation will take place in New York at 7:35 AM ET, with a live and 90-day replay available via Akebia's investor website. This engagement is part of the company's ongoing investor outreach efforts, following recent financial results and clinical progress updates.
Promising Penny Stocks To Consider In May 2026
This article identifies promising penny stocks for May 2026 within a robust U.S. market. It highlights Akebia Therapeutics (AKBA), Lineage Cell Therapeutics (LCTX), and loanDepot (LDI), discussing their financial health, challenges, and growth prospects. Despite typical penny stock risks like high debt or unprofitability, each company shows unique potential through clinical advancements, strong cash positions, or strategic partnerships.
Akebia plunges 20% on muted Q1 print
Akebia's stock fell by 20% following its first-quarter earnings report. The pharmaceutical company's Q1 results were described as muted, leading to a significant drop in its share price.
State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia
State Street Corporation has disclosed a passive ownership of 11,614,006 shares, representing a 4.3% stake, in Akebia Therapeutics Inc. as of March 31, 2026. This filing, a Schedule 13G, indicates that the shares are held for investment purposes rather than control, with shared voting power for 11,269,922 shares and shared dispositive power for all 11,614,006 shares. The report was signed by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer of State Street Corporation, on May 12, 2026.
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
Akebia Therapeutics, Inc. experienced a 23% stock drop after its first-quarter report, despite revenues beating expectations. Analysts have mixed opinions, downgrading revenue forecasts for 2026 and increasing per-share loss estimates, while the average price target remained unchanged at US$4.20. The company's revenue is expected to decline significantly, contrasting with the broader industry's forecast for growth.
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
Akebia Therapeutics (NASDAQ:AKBA) experienced a significant share price drop of 23% following its first-quarter results, despite revenues exceeding expectations. Analysts have mixed opinions, downgrading revenue forecasts to $216.2m for 2026 and increasing expected per-share losses to $0.13, while the average price target remained broadly unchanged at US$4.20, suggesting that the weaker earnings outlook may not impact long-term valuation. The company's projected revenue decline is steeper than the broader industry's expected growth.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Hold" from Analysts
Akebia Therapeutics (NASDAQ:AKBA) has an average analyst rating of "Hold" based on five brokerage coverages, with a split between two sell and three buy ratings, and an average 12-month price target of $4.67. Recent analyst actions included both upgrades and downgrades, while the company reported revenue exceeding estimates but missed EPS expectations. Shares opened near their 52-week low, and insider buying was also noted.
